 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5152535455565758596061...7475» |
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comparative study of anti-VEGF Ranibizumab and interleukin-6 receptor antagonist tocilizumab in adjuvant-induced arthritis. (Pubmed Central) - Mar 23, 2019
Also, they significantly reduced inflammatory, angiogenic and apoptotic markers. Importantly, Ranibizumab showed better effect than the standard anti-rheumatic drugs Methotrexate (MTX) or Tocilizumab (TCZ) in bone protection and cartilage health; hence proves to be a promising new therapeutic agent for RA.
- || Axpaxli (intravitreal axitinib implant) / Ocular Therap
Enrollment open, Trial initiation date: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Mar 22, 2019
P1, N=18, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Importantly, Ranibizumab showed better effect than the standard anti-rheumatic drugs Methotrexate (MTX) or Tocilizumab (TCZ) in bone protection and cartilage health; hence proves to be a promising new therapeutic agent for RA. Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Feb 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date, Trial primary completion date: SMILE: Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization (clinicaltrials.gov) - Mar 11, 2019
P4, N=54, Completed, Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Feb 2019 Recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial completion date, Trial primary completion date: CyPov: Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Mar 4, 2019
P4, N=28, Recruiting, Sponsor: Pusan National University Hospital
Recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018 Not yet recruiting --> Recruiting | Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Mar 2018 --> Sep 2019
- Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion: DIME: Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (clinicaltrials.gov) - Feb 19, 2019
P4, N=40, Completed, Sponsor: California Retina Consultants
Not yet recruiting --> Recruiting | Trial completion date: Aug 2018 --> Dec 2019 | Trial primary completion date: Mar 2018 --> Sep 2019 Active, not recruiting --> Completed
- | Lytenava (bevacizumab-vikg) / Outlook Therap
New P3 trial: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 18, 2019
P3, N=60, Recruiting, Sponsor: Outlook Therapeutics, Inc.
- | Lytenava (bevacizumab-vikg) / Outlook Therap
New P3 trial: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 8, 2019
P3, N=180, Not yet recruiting, Sponsor: Outlook Therapeutics, Inc.
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date: Retrospective Review of Proliferative Diabetic Retinopathy Patients (clinicaltrials.gov) - Feb 7, 2019
P=N/A, N=100, Active, not recruiting, Sponsor: Elman Retina Group
Active, not recruiting --> Completed Trial completion date: Dec 2018 --> Dec 2019
- ||| carotuximab ophthalmic (DE-122) / Tracon Pharma, Santen
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis (clinicaltrials.gov) - Feb 6, 2019
P2, N=76, Recruiting, Sponsor: Santen Inc.
Trial completion date: Dec 2018 --> Dec 2019 N=56 --> 76 | Trial completion date: Jul 2019 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
- | New P4 trial: STAMP: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (clinicaltrials.gov) - Feb 6, 2019
P4, N=32, Recruiting, Sponsor: Bay Area Retina Associates
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: RESCUE: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. (clinicaltrials.gov) - Feb 5, 2019
P1/2, N=12, Completed, Sponsor: Northern California Retina Vitreous Associates
N=56 --> 76 | Trial completion date: Jul 2019 --> Jan 2020 | Trial primary completion date: Jun 2019 --> Dec 2019 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jul 2018
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging (clinicaltrials.gov) - Feb 5, 2019
P=N/A, N=4, Terminated, Sponsor: Center for Eye Research Australia
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Jul 2018 N=100 --> 4 | Trial completion date: Dec 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Dec 2018; The delay between diagnosis and initiation of treatment was no longer consistent with standard of care
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - Jan 31, 2019
P=N/A, N=80, Recruiting, Sponsor: Medical University of Vienna
N=100 --> 4 | Trial completion date: Dec 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Dec 2018; The delay between diagnosis and initiation of treatment was no longer consistent with standard of care Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Biosci, Teva
Trial completion: COLUMBUS-AMD: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jan 29, 2019
P3, N=0, Completed, Sponsor: Bioeq GmbH
Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy, Monotherapy: ZIPANGU: Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety (clinicaltrials.gov) - Jan 28, 2019
P4, N=59, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
New P3 trial: XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) - Jan 15, 2019
P3, N=580, Not yet recruiting, Sponsor: Xbrane Biopharma AB
- ||| lemon balm extract (ALS-L1023) / Hanmi, AngioLab
Enrollment open, Combination therapy: Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD (clinicaltrials.gov) - Jan 10, 2019
P2, N=126, Enrolling by invitation, Sponsor: AngioLab, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- ||||||||| Xipere (triamcinolone acetonide) / Clearside Biomedical, Bausch Health, Arctic Vision
Trial completion date, Trial termination, Trial primary completion date, Combination therapy: TOPAZ: Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO (clinicaltrials.gov) - Jan 9, 2019
P3, N=323, Terminated, Sponsor: Clearside Biomedical, Inc.
Not yet recruiting --> Enrolling by invitation Trial completion date: Jun 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Dec 2018; The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP (clinicaltrials.gov) - Jan 9, 2019
P4, N=16, Completed, Sponsor: Universidad Autonoma de San Luis Potos
Trial completion date: Jun 2020 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Dec 2018; The early termination is due to the results obtained from the sister study, SAPPHIRE (CLS1003-301), which did not meet the 8-week primary efficacy endpoint. Recruiting --> Completed
- || JNJ-1887 / J&J
Enrollment change: AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) - Jan 8, 2019
P1, N=25, Recruiting, Sponsor: Hemera Biosciences
Recruiting --> Completed N=10 --> 25
- ||||| Byooviz (ranibizumab-nuna) / Samsung, AffaMed Therap, Biogen
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jan 3, 2019
P3, N=705, Active, not recruiting, Sponsor: Samsung Bioepis Co., Ltd.
N=10 --> 25 Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2019 | Trial primary completion date: Dec 2019 --> Jan 2019
- | Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
Trial completion date, Trial primary completion date: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Dec 24, 2018
P1/2, N=3, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Recruiting --> Active, not recruiting | Trial completion date: Jul 2020 --> Nov 2019 | Trial primary completion date: Dec 2019 --> Jan 2019 Trial completion date: Apr 2019 --> May 2020 | Trial primary completion date: Apr 2019 --> May 2020
- | Lucentis (ranibizumab) / Roche, Novartis, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
New P2/3 trial: CASSIE: Combined Ranibizumab and Iluvien for Diabetic Macular Oedema (clinicaltrials.gov) - Dec 21, 2018
P2/3, N=58, Not yet recruiting, Sponsor: Imperial College London
- | Lucentis (ranibizumab) / Roche, Novartis
Phase classification: ERASER: Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab (clinicaltrials.gov) - Dec 20, 2018
P4, N=40, Completed, Sponsor: California Retina Consultants
Trial completion date: Apr 2019 --> May 2020 | Trial primary completion date: Apr 2019 --> May 2020 Phase classification: P2/3 --> P4
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Intravitreal Ranibizumab (Lucentis (clinicaltrials.gov) - Dec 4, 2018
P2, N=10, Active, not recruiting, Sponsor: Sultan Qaboos University
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: RabOCT: Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT (clinicaltrials.gov) - Dec 3, 2018
P2b, N=27, Completed, Sponsor: University of Leipzig
Phase classification: P2/3 --> P4 Trial completion date: Dec 2015 --> Dec 2016 | Trial primary completion date: Apr 2015 --> Jun 2016
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: RANTA: Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Nov 30, 2018
P4, N=120, Active, not recruiting, Sponsor: Aier School of Ophthalmology, Central South University
Trial completion date: Dec 2015 --> Dec 2016 | Trial primary completion date: Apr 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Monotherapy: Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema (clinicaltrials.gov) - Nov 30, 2018
P4, N=12, Active, not recruiting, Sponsor: LUTRONIC Corporation
- | OPT-302 / Opthea
Enrollment closed, Combination therapy: A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD (clinicaltrials.gov) - Nov 28, 2018
P2, N=366, Active, not recruiting, Sponsor: Opthea Limited
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- | lemon balm extract (ALS-L1023) / Hanmi, AngioLab
Trial completion date, Trial primary completion date, Combination therapy: Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD (clinicaltrials.gov) - Nov 20, 2018
P2, N=126, Not yet recruiting, Sponsor: AngioLab, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Oct 2020 --> Dec 2020
- | Izervay (avacincaptad pegol intravitreal solution) / Astellas
Trial completion: ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) (clinicaltrials.gov) - Nov 15, 2018
P2a, N=65, Completed, Sponsor: Ophthotech Corporation
Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Oct 2020 --> Dec 2020 Recruiting --> Completed
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) - Nov 9, 2018
P=N/A, N=62, Recruiting, Sponsor: King's College Hospital NHS Trust
Recruiting --> Completed N=120 --> 62 | Trial primary completion date: Dec 2016 --> Jun 2019
- | lemon balm extract (ALS-L1023) / Hanmi, AngioLab
New P2 trial, Combination therapy: Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD (clinicaltrials.gov) - Oct 31, 2018
P2, N=126, Not yet recruiting, Sponsor: AngioLab, Inc.
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: Retrospective Review of Proliferative Diabetic Retinopathy Patients (clinicaltrials.gov) - Oct 29, 2018
P=N/A, N=100, Active, not recruiting, Sponsor: Elman Retina Group
N=120 --> 62 | Trial primary completion date: Dec 2016 --> Jun 2019 Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- | levosulpiride / Generic mfg.
Trial completion date, Trial primary completion date: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - Oct 23, 2018
P2, N=120, Recruiting, Sponsor: Carmen Clapp
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: May 2019 --> May 2020
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Oct 17, 2018
P4, N=110, Not yet recruiting, Sponsor: St. Erik Eye Hospital
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change: Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=17, Completed, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: May 2019 --> May 2020 Recruiting --> Completed | N=30 --> 17
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=30, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Completed | N=30 --> 17 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME (clinicaltrials.gov) - Sep 30, 2018
P4, N=72, Not yet recruiting, Sponsor: Beijing Hospital
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: aiRTo-PDR: 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial (clinicaltrials.gov) - Sep 24, 2018
P3, N=200, Recruiting, Sponsor: JUNYAN ZHANG
Active, not recruiting --> Completed Trial completion date: Jul 2017 --> Dec 2021 | Trial primary completion date: Dec 2016 --> Dec 2020
- | Fovista (pegpleranib) / Roche, Astellas
Trial completion: An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Sep 24, 2018
P1, N=30, Completed, Sponsor: Retinal Consultants of Arizona
Trial completion date: Jul 2017 --> Dec 2021 | Trial primary completion date: Dec 2016 --> Dec 2020 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) (clinicaltrials.gov) - Sep 14, 2018
P1/2, N=40, Completed, Sponsor: David M. Brown, M.D.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | JNJ-1887 / J&J
Enrollment open: AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) - Sep 14, 2018
P1, N=10, Recruiting, Sponsor: Hemera Biosciences
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis, Fovista (pegpleranib) / Roche, Astellas
Trial completion date, Trial primary completion date: A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (clinicaltrials.gov) - Sep 13, 2018
P1/2, N=3, Active, not recruiting, Sponsor: National Eye Institute (NEI)
Not yet recruiting --> Recruiting Trial completion date: Aug 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Apr 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide (clinicaltrials.gov) - Sep 11, 2018
P1, N=4, Completed, Sponsor: Soll Eye
Trial completion date: Aug 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Apr 2019 Recruiting --> Completed | N=20 --> 4 | Trial completion date: Nov 2020 --> Sep 2018 | Trial primary completion date: Nov 2019 --> Sep 2018
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema (clinicaltrials.gov) - Sep 7, 2018
P4, N=40, Completed, Sponsor: Shinshu University
Recruiting --> Completed | N=20 --> 4 | Trial completion date: Nov 2020 --> Sep 2018 | Trial primary completion date: Nov 2019 --> Sep 2018 Recruiting --> Completed
- | carotuximab ophthalmic (DE-122) / Tracon Pharma, Santen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis (clinicaltrials.gov) - Sep 6, 2018
P2, N=56, Recruiting, Sponsor: Santen Inc.
Recruiting --> Completed Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Feb 2019 --> Jun 2019
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial completion date, Trial primary completion date: PROTECT: Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Aug 28, 2018
P1/2, N=4, Completed, Sponsor: Leonard Feiner, MD, PhD
Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Feb 2019 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jul 2018 | Trial primary completion date: Jul 2017 --> Jul 2018
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Aug 22, 2018
P4, N=0, Withdrawn, Sponsor: Federal University of S
Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Jul 2018 | Trial primary completion date: Jul 2017 --> Jul 2018 N=30 --> 0
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
New P1 trial: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Aug 13, 2018
P1, N=25, Not yet recruiting, Sponsor: Ocular Therapeutix, Inc.